Possibilities of using the values of vascular wall function as markers of negative metabolic effects of treatment with thiazide diuretics in patients with essential hypertension

Terapevticheskii Arkhiv

Volumn 79, Issue 4, 2007, Pages 31-38

  Semenkin, A A ^a  

^a NONE

Author keywords

Coronary risk; Hypertensive disease; Metabolic effects; Thiazide diuretics; Vascular endothelium

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDAPAMIDE; LIPID METABOLISM; MALE; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME; VASODILATION;

EID: 34249673454     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. World Health Organization, International Society on Hypertension Writing Group. 2003 World Health Organization (WHO) / International Society on Hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003; 21: 1983-1992.
2. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21 (6): 1011-1053.
3. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prevent. Rehabil. 2003; 10 (suppl. 1): S1-S78.
4. Yusuf H. R., Giles W. H., Croft J. B. et al. Impact of multiple risk factors profiles on determining cardiovascular disease risk. Prev. Med. 1998; 27 (1): 1-9.
5. Lloyd-Jones E. M., Evans J. C., Larson M. G. et al. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch. Intern. Med. 1999; 159: 2206-2212.
6. Eaton C. B., Feldman H. A., Assaf A. R. et al. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. J. Fam. Pract. 1994; 38: 17-23.
7. Stern N., Grosskopf I., Shapira I. et al. Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines. J. Intern. Med. 2000; 248: 203-210.
8. Genest J. Jr., Cohn J. S. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am. J. Cardiol. 1995; 76 (2): 8A-20A.
9. Raitakari O. T., Porkka K. V., Rasanen L. et al. Clustering and six year cluster-tracking of serum total cholesterol, HDL-cholesterol and diastolic blood pressure in children and young adults: the Cardiovascular Risk in Young Finns Study. J. Clin. Epidemiol. 1994; 47: 1085-1093.
10. Quyyumi A. A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am. J. Med. 1998; 105 (suppl. 1A): 32S-39S.
11. Biegelsen E. S., Loscalzo J. Endothelial function and atherosclerosis. Coron. Artery Dis. 1999; 10 (4): 241-256.
12. Gambardella S., Frontoni S., Pellegrinotti M. et al. Carbohydrate metabolism in hypertension: influence of treatment. J. Cardiovasc. Pharmacol. 1993; 22 (suppl. 6): S87-S97.
13. Brook R. D. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr. Hypertens. Rep. 2000; 2: 370-377.
14. Spieker L. E., Noll G., Ruschitzka F. T. et al. Working under pressure: the vascular endothelium in arterial hypertension. J. Hum. Hypertens. 2000; 14: 617-630.
15. Lind L., Granstam S.-O., Millgard J. Endothelium-dependent vasodilation in hypertension: A review. Blood Press. 2000; 9: 4-15.
16. Zanchetti A., Rosei E. A., Dal Palu C. et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. 1998; 16 (11): 1667-1676.
17. Motro M., Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410-1413.
18. Zanchetti A., Bond M. G., Hennig M. et al. on behalf of the ELSA investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427.
19. Zanchetti A., Crepaldi G., Bond G. et al. Effects of fosinopril and pravastatin on progression of asymptomatic carotid atherosclerosis in hypertension: results of the Plaque Hypertension Lipid lowering Italian Study (PHYLLIS). J. Hypertens. 2003; 21 (suppl. 4): S345.
20. Andersson O. K., Almgren T., Persson D. et al. Survival in treated hypertension: follow up study after two decades. Br. Med. J. 1998; 317: 167-171.
21. Dunder K., Lind L., Zethelius B. et al. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Br. Med. J. 2003; 326: 681-685.
22. Verdecchia P., Reboldi G., Angeli I. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
23. Joint Recomendations of the British Cardiac Society, British Hyperlipidemia Association, British Diabetic Association on Prevention of Coronary Heart Disease in Clinical Practice. Heart 1998; 80 (suppl. 2): 1-28.
24. Al Suwaidi J. A., Hamasaki S., Higano S. T. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
25. Neunteufl T., Heher S., Katzenschlager R. et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am. J. Cardiol. 2000; 86: 207-210.
26. Schachinger V., Britten M. B., Zeiher A. M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
27. Heitzer T., Schlinzig T., Krohn K. et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
28. Perticone F., Ceravolo R., Pujia A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-196.
29. Gokce N., Keaney J. F. Jr., Hunter L. M. et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J. Am. Coll. Cardiol. 2003; 41: 1769-1775.
30. Targonski P. V., Bonetti P. O., Pumper G. M. et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003; 107: 2805-2809.
31. Sica D. A. Diuretic-related side effects: development and treatment. J. Clin. Hypertens. 2004; 6 (9): 532-540.
32. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf. 2001; 24 (15): 1155-1165.
33. Kuo S. W., Hung Y. J., Hsieh A. T. et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am. J. Hypertens. 2003; 16 (8): 623-628.
34. Wilson P. W., D'Agostino R. B., Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97 (18): 1837-1847.
35. Celermajer D. S., Sorensen K. E., Gooch V. M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
36. Russian source
37. Pollare T., Lithell H., Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 1989; 321: 868-837.
38. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. A. M. A. 2002; 288: 2981-2997.
39. Mantel-Teeuwisse A. K., Kloosterman J. M., Maitland-van der Zee A. H. et al. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf. 2001; 24: 443-456.
40. Kasiske B. L., Ma J. Z., Kalil R. S. et al. Effects of antihypertensive therapy on serum lipids. Ann. Intern. Med. 1995; 122: 133-141.
41. Kris-Etherton P. M., Pearson T. A., Wan Y. et al. High-monounsaturated fatty acid diets lower both plasma cholesterol and triaglycerol concentrations. Am. J. Clin. Nutr. 1999; 70: 1009-1015.
42. Kasim-Karakas S. E., Almario R. U., Mueller W. M. et al. Changes in plasma lipoproteins during low-fat, high-carbohydrate diets: effects of energy intake. Am. J. Clin. Nutr. 2000; 71: 1439-1447.
43. Lind L., Pollare T., Berne C., Lithell H. Long-term metabolic effects of antihypertensive drugs. Am. Heart J. 1994; 128 (6, pt 1): 1177-1183.
44. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335 (8693): 827-838.
45. Bonetti P. O., Lerman L. O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb. Vase. Biol. 2003; 23: 168-175.
46. Modena M. G., Bonetti L., Coppi F. et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J. Am. Coll. Cardiol. 2002; 40: 505-510.
47. Numabe A., Uehara Y., Hirawa N. et al. Effects of thiazide diuretic on vascular eicosanoid system of spontaneously hypertensive rats. J. Hypertens. 1989; 7 (6): 493-499.
48. Higashi Y., Sasaki S., Nakagawa K. et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J. Am. Coll. Cardiol. 2000; 35 (2): 284-291.
49. Klingbeil A. U., John S., Schneider M. P. et al. Effect of ATI receptor blockade on endothelial function in essential hypertension. Am. J. Hypertens. 2003; 16 (2): 123-128.
50. Chung N. A., Beevers D. G., Lip G. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press. 2004; 13 (3): 183-189.
51. Muiesan M. L., Salvetti M., Monteduro C. et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999; 33 (1, pt 2): 575-580.
52. Dell'omo G., Penno G., Del Prato S., Pedrinelli R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J. Cardiovasc. Pharmacol. Ther. 2005; 10 (4): 265-272.
53. Uehara X., Kawabata Y., Shirahase H. et al. Oxygen radical scavengers and renal protection by indapamide diuretic in salt-induced hypertension of Dahl strain rats. J. Cardiovasc. Pharmacol. 1993; 22 (suppl. 6): S42-S46.
54. Schini V. B., Dewey J., Vanhoutte P. M. Effects of indapamide on endothelium-dependent relaxations in isolated canine femoral arteries. Am. J. Cardiol. 1990; 65 (17): 6H-10H.
55. Delbarre B., Delbarre G., Ferger A. Role of prostaglandins in the mechanism of action of indapamide. Arch. Mal. Coeur. 1990; 83 (8): 1209-1212.
56. Boulanger C. M., Mombouli J. V., Vanhoutte P. M. Indapamide inhibits endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Fundam. Clin. Pharmacol. 1993; 7 (8): 443-448.
57. Wheatcroft S. B., Williams I. L., Shah A. M., Keamey M. T. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet. Med 2003; 20: 255-268.
58. Scherrer U., Sartori C. Insulin as a vascular and sympathoexcitatory hormone. Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104-4113.
59. Mikhail N., Tuck M. L. Insulin and the vasculature. Curr. Hypertens. Rep. 2000; 2: 148-153.
60. Ritchie S. A., Ewart M.-A., Perry C. G. et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin. Sci. 2004; 107: 519-532.
61. Festa A., Hartley A. J. G., Tracy R. P. et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003; 108: 1822-1830.
62. Stump C. S., Clark S. E., Sowers J. R. Oxidative stress in insulin-resistant conditions: cardiovascular implications. Treat Endocrinol. 2005; 4 (6): 343-351.
63. Norlander M. Target organs in hypertension: the vascular tree. In: Messerli F. H., ed. The ABC of antihypertensive therapy. New York: Raven Press, Author' Publishing House; 1994. 27-36.
64. Cockcroft J. R., Webb D. J., Wilkinson I. B. Arterial stiffness, hypertension and diabetes mellitus. J. Hum. Hypertens. 2000; 14: 377-380.
65. Wilkinson I. B., Qasem A., McEniery C. M. et al. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105: 213-217.
66. Del Rio M., Chulia T., Merchan-Perez A. et al. Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits. J. Cardiovasc. Pharmacol. 1995; 25 (6): 973-978.
67. Lebrillant E., Roulet M. J., Robert R. et al. Study of antiatherogenic properties of indapamide in a pharmacologic model. J, Cardiovasc. Pharmacol. 1993; 22 (suppl. 6): S53-S56.